Nirsevimab for Prevention of RSV in Healthy Late-preterm and Term Infants. Issue 3 (24th September 2022)

• Record Type: Journal Article
• Authors: Hammitt, L.L.; Dagan, R.; Yuan, Y.; Baca Cots, M.; Bosheva, M.; Madhi, S.A.; Muller, W.J.; Zar, H.J.; Brooks, D.; Grenham, A.; Wählby Hamrén, U.; Mankad, V.S.; Ren, P.; Takas, T.; Abram, M.E.; Leach, A.; Griffin, M.P.; Villafana, T.
• Is Part Of: Obstetric anesthesia digest. Volume 42:Issue 3(2022)
• Page Start: 140
• Page End: 141
• Publication Date: 2022-09-24
• Subjects: Neonatal Morbidity and Mortality -- Pharmacology -- Infection and Sepsis; Anesthesia in obstetrics -- Periodicals; Anesthesia in obstetrics -- Abstracts -- Periodicals; 617.968205
• DOI: 10.1097/01.aoa.0000853608.92586.4e
• Languages: English
• ISSNs: 0275-665X

Abstract

Abstract : ( N Engl J Med . 2022;386:837–846. doi: 10.1056/NEJMoa2110275) Infants experience medically attended illness and hospitalization at elevated rates from respiratory syncytial virus (RSV) infection. As a monoclonal antibody with an extended half-life, Nirsevimab (N) is an emerging treatment that binds to the RSV fusion protein and has enhanced inhibitory potency for RSV in cell-culture and animal models over Palivizumab. Preterm (29 to <35 wk gestational age birth) infants receiving a single dose of N before RSV season showed 70.1% efficacy at protection against RSV with a favorable safety profile. The safety and efficacy of N in late-preterm and term infants entering their first RSV season is investigated in this phase 3 trial.